SYNCHRONIZE-1 Through a Hepatologist's Lens: Liver Fat Reduction, Visceral Fat, and What Comes Next

In 'SYNCHRONIZE-1 Through a Hepatologist's Lens: Liver Fat Reduction, Visceral Fat, and What Comes Next,' Nadege Gunn, MD delves into the following critical questions:

SYNCHRONIZE-1 trial data was just announced at the ADA Scientific Sessions showing an average weight loss of 16% and up to 63% reduction in liver fat. As a hepatologist, how do you interpret a liver fat reduction of that size — and what does the literature tell us to expect in terms of disease resolution and outcomes improvement with that degree of hepatic fat reduction?

How does visceral fat reduction specifically, as distinct from total body weight loss, translate into hepatic benefit in your clinical experience, and why is that distinction meaningful for your MASH patients?

As a hepatologist, what would you want to see from a MASH-focused trial for this therapeutic class, and what endpoints would best demonstrate liver-specific benefit beyond what SYNCHRONIZE-1 was designed to capture?

Gunn described her reaction to the SYNCHRONIZE-1 liver fat reduction data as genuinely compelling from a hepatology perspective, noting a reduction of up to 63% represents a level of hepatic fat clearance that could meaningfully transform the disease trajectory for patients, with the data also demonstrating reductions in non-invasive markers of fibrosis such as ELF and Pro-C3, adding further weight to the possibility that this combination could address not just fat accumulation but the fibrotic progression that drives the most serious liver-related morbidity. She also highlighted the particular clinical significance of visceral fat reduction and that demonstrable reductions in visceral adiposity signal a meaningful disruption of the metabolic cascade that fuels hepatic inflammation and fibrosis. Gunn further outlined what she would want to see from future MASH-specific trials for this therapeutic class, calling for histologic endpoints, representation of minority populations that have historically been underrepresented in MASH trials, and expanded use of non-invasive biomarkers including MRI-based fat quantification, ELF, and Pro-C3, data that would allow clinicians to more precisely tailor dual incretin therapy to the patients most likely to derive hepatic benefit.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, 'Transplants, Decompensation, and the True Cost of Untreated MASH,' features Nadege Gunn advancing her conversation on obesity and MASH and focusing on the stark economic contrast between the cost of early pharmacologic intervention in MASH and the high healthcare utilization associated with late-stage complications.